Sökning: WFRF:(Eisenstat David D.) > Outcomes of BRAF V6...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06016naa a2201153 4500 | |
001 | oai:gup.ub.gu.se/299017 | |
003 | SwePub | |
008 | 240528s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2990172 URI |
024 | 7 | a https://doi.org/10.1200/PO.19.002982 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Nobre, Liana4 aut |
245 | 1 0 | a Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition |
264 | 1 | c 2020 |
520 | a © 2020 by American Society of Clinical Oncology PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (P, .001). These responses were rapid (median, 4 months) and sustained in 86% of tumors up to 5 years while receiving therapy. After discontinuation of BRAF inhibition, 76.5% (13 of 17) of patients with PLGG experienced rapid progression (median, 2.3 months). However, upon rechallenge with BRAF inhibition, 90% achieved an objective response. Poor prognostic factors in conventional therapies, such as concomitant homozygous deletion of CDKN2A, were not associated with lack of response to BRAF inhibition. In contrast, only 36% of those with PHGG responded to BRAF inhibition, with all but one tumor progressing within 18 months. In PLGG, responses translated to 3-year progression-free survival of 49.6% (95% CI, 35.3% to 69.5%) versus 29.8% (95% CI, 20% to 44.4%) for BRAF inhibition versus chemotherapy, respectively (P = .02). CONCLUSION Use of BRAF inhibition results in robust and durable responses in BRAF V600E–mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Zapotocky, Michal4 aut |
700 | 1 | a Ramaswamy, Vijay4 aut |
700 | 1 | a Ryall, Scott4 aut |
700 | 1 | a Bennett, Julie4 aut |
700 | 1 | a Alderete, Daniel4 aut |
700 | 1 | a Guill, Julia Balaguer4 aut |
700 | 1 | a Baroni, Lorena4 aut |
700 | 1 | a Bartels, Ute4 aut |
700 | 1 | a Bavle, Abhishek4 aut |
700 | 1 | a Bornhorst, Miriam4 aut |
700 | 1 | a Boue, Daniel R.4 aut |
700 | 1 | a Canete, Adela4 aut |
700 | 1 | a Chintagumpala, Murali4 aut |
700 | 1 | a Coven, Scott L.4 aut |
700 | 1 | a Cruz, Ofelia4 aut |
700 | 1 | a Dahiya, Sonika4 aut |
700 | 1 | a Dirks, Peter4 aut |
700 | 1 | a Dunkel, Ira J.4 aut |
700 | 1 | a Eisenstat, David4 aut |
700 | 1 | a Conter, Cecile Faure4 aut |
700 | 1 | a Finch, Elizabeth4 aut |
700 | 1 | a Finlay, Jonathan L.4 aut |
700 | 1 | a Frappaz, Didier4 aut |
700 | 1 | a Garre, Maria Luisa4 aut |
700 | 1 | a Gauvain, Karen4 aut |
700 | 1 | a Bechensteen, Anne Grete4 aut |
700 | 1 | a Hansford, Jordan R.4 aut |
700 | 1 | a Harting, Inga4 aut |
700 | 1 | a Hauser, Peter4 aut |
700 | 1 | a Hazrati, Lili Naz4 aut |
700 | 1 | a Huang, Annie4 aut |
700 | 1 | a Injac, Sarah G.4 aut |
700 | 1 | a Iurilli, Valentina4 aut |
700 | 1 | a Karajannis, Matthias4 aut |
700 | 1 | a Kaur, Gurcharanjeet4 aut |
700 | 1 | a Kyncl, Martin4 aut |
700 | 1 | a Krskova, Lenka4 aut |
700 | 1 | a Laperriere, Normand4 aut |
700 | 1 | a Larouche, Valerie4 aut |
700 | 1 | a Lassaletta, Alvaro4 aut |
700 | 1 | a Leary, Sarah4 aut |
700 | 1 | a Lin, Frank4 aut |
700 | 1 | a Mascelli, Samantha4 aut |
700 | 1 | a McKeown, Tara4 aut |
700 | 1 | a Milde, Till4 aut |
700 | 1 | a la Madrid, Andres Morales4 aut |
700 | 1 | a Morana, Giovanni4 aut |
700 | 1 | a Morse, Helena4 aut |
700 | 1 | a Mushtaq, Naureen4 aut |
700 | 1 | a Osorio, Diana S.4 aut |
700 | 1 | a Packer, Roger4 aut |
700 | 1 | a Pavelka, Zdenek4 aut |
700 | 1 | a Quiroga-Cantero, Eduardo4 aut |
700 | 1 | a Rutka, James4 aut |
700 | 1 | a Sabel, Magnus,d 1966u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics4 aut0 (Swepub:gu)xsabma |
700 | 1 | a Salgado, Duarte4 aut |
700 | 1 | a Solano, Palma4 aut |
700 | 1 | a Sterba, Jaroslav4 aut |
700 | 1 | a Su, Jack4 aut |
700 | 1 | a Sumerauer, David4 aut |
700 | 1 | a Taylor, Michael D.4 aut |
700 | 1 | a Toledano, Helen4 aut |
700 | 1 | a Tsang, Derek S.4 aut |
700 | 1 | a Fernandes, Mariana Valente4 aut |
700 | 1 | a van Landeghem, Frank4 aut |
700 | 1 | a van Tilburg, Cornelis M.4 aut |
700 | 1 | a Wilson, Bev4 aut |
700 | 1 | a Witt, Olaf4 aut |
700 | 1 | a Zamecnik, Josef4 aut |
700 | 1 | a Bouffet, Eric4 aut |
700 | 1 | a Hawkins, Cynthia4 aut |
700 | 1 | a Tabori, Uri4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för pediatrik4 org |
773 | 0 | t JCO Precision Oncologyg 3, s. 561-571q 3<561-571x 2473-4284 |
856 | 4 8 | u https://gup.ub.gu.se/publication/299017 |
856 | 4 8 | u https://doi.org/10.1200/PO.19.00298 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy